The review article updates on the key challenge in the present-day cardiology duration of dual antiplatelet therapy (DAPT) in patients with a history of acute coronary syndrome. The relevant clinical guidelines are analyzed, and results of the recent clinical trials and meta-analyses are highlighted. A risk assessment scale for evaluating ischemic and bleeding risks based on the study of DAPT is presented.